Context Therapeutics

PHILADELPHIA, PA · Founded 2021 · CIK 0001842952 · Biotech · Public

Therapeutics for female cancers

contexttherapeutics.com →
Grants
$450K
2 awards
Sector median: 1
Raised
$100M
1 Form D · May 2024
29 months since last filing
Contracts
—
No federal contracts on record
Patents
10
0 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Potent Small Molecule Sigma1 Modulator Degrades Androgen Receptor In Castration Resistant Prostate Cancer$225,222
Federal grantDepartment of Health and Human Services · Phase I · A Potent Small Molecule Sigma1 Modulator Degrades Androgen Receptor In Castration Resistant Prostate Cancer$225,222
Private capital raisedForm D · SEC$99,992,767
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2168Ocugen—$126M
2169VISIONARY PHARMACEUTICALS, INC.——
2170Excision BioTherapeutics Inc.—$71M
2171Context Therapeutics—$100M
2172QT Holdings Corp.—$3.8M
2173LOKI THERAPEUTICS, INC——
2174Aruvant Sciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Richard BermanDirector
  • Jennifer Evans StaceyDirector
  • Philip KantoffDirector
  • Martin LehrDirector · Executive Officer
  • Alex LevitExecutive Officer
  • Jennifer Minai-AzaryExecutive Officer
  • Linda WestDirector

Patents

USPTO · 0 granted of 10
  • Bispecific Antibodies And Methods Of Using The Sameapplication
  • Compositions Comprising Bispecific Antibodies That Bind To Claudin 6 And CD3, And Uses Thereofapplication
  • Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
  • Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
  • Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
  • Compositions Comprising Bispecific Antibodies That Bind To Claudin 6 And CD3, And Uses Thereofapplication
  • Methods Of Identifying And Treating Tumors With SIGMA1 Inhibitorsapplication
  • Bispecific Antibodies And Methods Of Using The Sameapplication
  • Compositions Comprising Bispecific Antibodies That Bind To Claudin 6 And CD3, And Uses Thereofapplication
  • Bispecific Antibodies And Methods Of Using The Sameapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.